RBC Capital Maintains Sector Perform Rating for Bio-Techne: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
RBC Capital has maintained its Sector Perform rating for Bio-Techne (NASDAQ:TECH) but lowered its price target from $85.00 to $75.00. Bio-Techne's shares have fallen 4.06% in the last 24 hours to $65.76. A move to the new target price would represent a 14.05% increase. Bio-Techne, a life sciences manufacturer, operates primarily in protein sciences and diagnostics and genomics, with the U.S. being its largest market.
February 02, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains Sector Perform rating for Bio-Techne but lowers price target from $85 to $75. Shares have dropped 4.06% to $65.76, indicating potential for a 14.05% increase to the new target.
The maintenance of the Sector Perform rating by RBC Capital suggests a neutral outlook on Bio-Techne's stock, while the reduction in the price target could reflect adjustments in valuation metrics or market conditions. The current share price drop and the potential for a 14.05% increase to the new target price indicate a short-term opportunity for investors, assuming market conditions align with RBC Capital's analysis.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100